WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 406357
Description: CEP-6800 is a potent PARP inhibitor with potential anticancer activity. CEP-6800 could be used as a chemopotentiating agent with a variety of clinically effective chemotherapeutic agents.
MedKoo Cat#: 406357
Chemical Formula: C18H15N3O2
Exact Mass: 305.11643
Molecular Weight: 305.33
Elemental Analysis: C, 70.81; H, 4.95; N, 13.76; O, 10.48
CEP-6800 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to firstname.lastname@example.org to inquire quote.
Synonym: CEP6800; CEP 6800; CEP-6800.
IUPAC/Chemical Name: 10-(aminomethyl)-4,5,6,7-tetrahydro-1H-cyclopenta[a]pyrrolo[3,4-c]carbazole-1,3(2H)-dione
InChi Key: SDXBGOVSVBZDFL-UHFFFAOYSA-N
InChi Code: InChI=1S/C18H15N3O2/c19-7-8-4-5-12-11(6-8)13-15-14(17(22)21-18(15)23)9-2-1-3-10(9)16(13)20-12/h4-6,20H,1-3,7,19H2,(H,21,22,23)
SMILES Code: O=C1NC(C2=C1C3=C(C4=C2CCC4)NC5=C3C=C(CN)C=C5)=O
The following data is based on the product molecular weight 305.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Guggenheim ER, Ondrus AE, Movassaghi M, Lippard SJ. Poly(ADP-ribose) polymerase-1 activity facilitates the dissociation of nuclear proteins from platinum-modified DNA. Bioorg Med Chem. 2008 Dec 1;16(23):10121-8. doi: 10.1016/j.bmc.2008.09.074. Epub 2008 Oct 14. PubMed PMID: 18977144; PubMed Central PMCID: PMC2662712.
2: Haince JF, Rouleau M, Hendzel MJ, Masson JY, Poirier GG. Targeting poly(ADP-ribosyl)ation: a promising approach in cancer therapy. Trends Mol Med. 2005 Oct;11(10):456-63. Epub 2005 Sep 8. Review. PubMed PMID: 16154385.
3: Miknyoczki SJ, Jones-Bolin S, Pritchard S, Hunter K, Zhao H, Wan W, Ator M, Bihovsky R, Hudkins R, Chatterjee S, Klein-Szanto A, Dionne C, Ruggeri B. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol Cancer Ther. 2003 Apr;2(4):371-82. PubMed PMID: 12700281.